Akeso's Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis

Resumen detallado
HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug…
HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for gumokimab, its self-developed IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). Active AS marks the second approved indication for gumokimab. In June 2026, gumokimab received approval in China for moderate-to-severe plaque psoriasis.
The AS approval is supported by the positive results of the pivotal Phase 3 registration study AK111-303. The study met all pre-specified efficacy endpoints, demonstrating that gumokimab provides rapid, robust, and sustained relief of AS symptoms while significantly improving disease activity, physical function, and quality of life.
Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the sacroiliac joints, spine, and peripheral joints. In severe cases, it can result in spinal deformity and functional impairment, substantially impacting patients' quality of life. IL-17A is a key pro-inflammatory cytokine implicated in the pathogenesis of autoimmune diseases such as psoriasis and ankylosing spondylitis. Gumokimab binds specifically and with high affinity to human IL-17A, blocking its interaction with IL-17 receptor A (IL-17RA) expressed on T cells, natural killer cells, and antigen-presenting cells, thereby inhibiting the downstream inflammatory cascade.
Professor Rong Mu, Principal Investigator of AK111-303 and Professor at Peking University Third Hospital, stated: "Clinical management of this disease continues to present significant challenges, and current treatment options do not fully address patients' needs regarding depth of response, long-term disease control, and accessibility.
Dr. Michelle Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso, commented: "We extend our sincere thanks to the investigators, study teams, and patients who participated in the…
Inicio del artículo, extracto de PR Newswire. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)
